ADC Therapeutics Sarl logo

ADC Therapeutics SA

ADC Therapeutics Sarl (ADCT), is a Swiss-based oncology drug development company, and specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting cancers.

ADC was established by PE firm Auven Therapeutics and is located in Lausanne, Switzerland. It utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK. ADC has manufacturing and clinical studies managed from its US offices in San Francisco and New Jersey.

Research Pipeline
BioStartup's Score 0 / 50


Disease Focus
Development Stage
Route de la Corniche 3B 1066
Contact Number
+41 2-1653-0200

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]

ADC is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematological cancers and employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.


ADCs lead lymphoma drug candidates ADCT-301 and ADCT-402 are currently in four clinical studies in relevant sub-types of lymphoma and leukemia.

ADCT-301 combines HuMaxë-TAC_, a monoclonal antibody targeting CD25 (the alpha chain of the IL-2 receptor) created by Genmab A/S, a biotechnology company, based in Copenhagen, Denmark, with a highly potent pyrrolobenzodiazepine (PBD)-based warhead. The company says that ADCT-301 showed promising anti-tumour activity preclinically, outperforming Seattle Genetics approved ADC drug brentuximab vedotin (Adcetris). ADCT- ADCT-402 is a similar construct targetting CD19, a surface protein expressed throughout B-cell development on nearly all B-cell malignancies in many non- Hodgkin lymphomas.

Furthermore, the company wants to file INDs for ADCT-602 and ADCT-601, and to progress unpublished preclinical pipeline programmes.

In Nov 2013, ADC licensed proprietary antibodies from Five Prime Therapeutics to develop antibody-drug conjugates. In Jul 2013, ADC licensed an antibody from BZL Biologics to develop PSMA-specific ADC against PSMA-positive prostate cancers.

In Jun 2013, ADC licensed an antibody VM101 from VivaMab to combine with a third generation cytotoxic PBD-based warhead and proprietary linker technology to form a novel ADC to target Hematologic Cancers.

ADC Therapeutics has a strategic collaboration with Spirogen Ltd, (AstraZenca acquired Spriogen in 2013), for the supply of warhead chemistries and other R&D services.

In Oct 2013, MedImmune (AstraZeneca) entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCTs antibody-drug conjugate programs in preclinical development.

In 2013, Genmab and ADC Therapeutics Enter Co-Development, 50:50 partnership for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead.

In Aug 2017, ADC raised US$200 Mn through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca. Earlier in 2016 raised $105 Mn through a private placement.

In Sep 2015, ADC Therapeutics raised $80 Mn through a private placement of equity to Progress Its pipeline of Antibody Drug Conjugate therapeutics in Oncology.

In 2012, ADC Therapeutics secured $50 Mn as a seed fund from private equity firm Auven Therapeutics (formely Celtic Therapeutics). In 2013 AstraZeneca took an equity stake in the Company, investing $20 Mn.